In today’s recent session, 43.63 million shares of the ZyVersa Therapeutics Inc (NASDAQ:ZVSA) have been traded, and its beta is 0.66. Most recently the company’s share price was $0.76, and it changed around $0.21 or 37.37% from the last close, which brings the market valuation of the company to $2.75M. ZVSA at last check was trading at a discount to its 52-week high of $6.69, offering almost -780.26% off that amount. The share price’s 52-week low was $0.55, which indicates that the recent value has risen by an impressive 27.63% since then.
ZyVersa Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ZVSA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
ZyVersa Therapeutics Inc (NASDAQ:ZVSA) trade information
Instantly ZVSA has been showing a green trend so far today with a performance of 37.37% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.7200 on recent trading daydecreased the stock’s daily price by -5.56%. The company’s shares are currently down -28.57% year-to-date, but still up 24.15% over the last five days. On the other hand, ZyVersa Therapeutics Inc (NASDAQ:ZVSA) is 30.10% up in the 30-day period.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 58.00%.
ZVSA Dividends
ZyVersa Therapeutics Inc’s next quarterly earnings report is expected to be released in June.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 18.08 shares worth $14283.0, making up 0.50% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund held roughly 3.63 shares worth around $2864.0, which represents about 0.10% of the total shares outstanding.
